Furthermore, data from a clinical trial on a relatively large cohort, in terms of the rate of MET exon 14 mutations (n=69), showed encouraging outcomes in patients with advanced NSCLC and MET exon 14 skipping, with a 9.1 month median duration of response and a 7.3 month median progression free-survival (Drilon et al., 2020). This evidence concerns the gene MET and non-small cell lung carcinoma.